Status:
ENROLLING_BY_INVITATION
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Lead Sponsor:
LMU Klinikum
Collaborating Sponsors:
Medical Park AG
Conditions:
Inclusion Body Myositis
Myotonic Dystrophy
Eligibility:
All Genders
18-65 years
Brief Summary
Currently, there are no standardised fall risk scores or guidelines on when to use appropriate assistive gait devices (AGDs) for people with neuromuscular disorders (NMDs). There is a clear medical un...
Detailed Description
The NMD people are characterised by a complex muscle weakness caused by a combination of different factors. These include reduced endurance, lack of explosive muscle force and power, intramuscular str...
Eligibility Criteria
Inclusion
- Only patients with adequate cognitive and communicative function to give informed consent and to fill out the scale assessing the risk of falling will be included.
Exclusion
- Patients who are unable to walk without AGD for at least 10 meters.
- Patients who had knee, hip or back surgery in the last three months.
- Patients who suffer from polyneuropathy or peripheral neuropathy.
Key Trial Info
Start Date :
September 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06605612
Start Date
September 9 2024
End Date
January 1 2028
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, LMU Klinikum, Ludwig-Maximilians-Universität München
München, Bavaria, Germany, 80336